生物制药公司Tarsus Pharmaceuticals, Inc.宣布,其创新口服片剂TP-05(洛替拉纳)用于潜在预防莱姆病的二期临床试验"Calliope"已完成首例受试者给药。该研究旨在评估这款基于lotilaner成分的试验性药物在疾病预防领域的应用前景。
生物制药公司Tarsus Pharmaceuticals, Inc.宣布,其创新口服片剂TP-05(洛替拉纳)用于潜在预防莱姆病的二期临床试验"Calliope"已完成首例受试者给药。该研究旨在评估这款基于lotilaner成分的试验性药物在疾病预防领域的应用前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.